Christian Rohlff
Chief Executive Officer & Founder Oxford BioTherapeutics Ltd
Seminars
Monday 8th June 2026
Leveraging OGAP®-Verify to Identify & Target Multiple Tumor-Associated Antigens (TAAs) to Drive Improved Efficacy, Overcome Heterogeneity, & Minimize Immune Escape
4:30 pm
- Multi-TAA TCEs deliver broader tumor targeting with and more robust anti- tumor activity by simultaneously engaging multiple antigens and T-cells
- Addresses tumor heterogeneity by targeting multiple TAAs simultaneously
- Reduces immune escape by lowering chance of single antigen loss
- Enhanced T-cell activation leads to stronger and more sustained cytotoxicity
- Improved clinical potential with higher response rates and durability
